The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.39 — safe zoneOK
Leadership changes
From Coya Therapeutics, Inc.'s own filings, the day they're filed.
- Mark H. Pavao · director · departureeff. 2026-04-01
- Howard Berman · directors · departureeff. 2026-04-01
- Arun Swaminathan · Chief Executive Officer · appointmenteff. 2024-11-01
Latest filings
- DEF 14A · Annual proxy (pay & governance)2026-05-13
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-12
- 8-K · Company announcement2026-04-02
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Coya Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Coya Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.